Tessa Therapeutics Announces Positive Data from Phase 2 Trial of Autologous CD30-CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma at 2021 ASH Annual Meeting
Oral poster highlights data from 14 heavily pre-treated patients enrolled in pilot stage of multicenter, open-label, single arm CHARIOT study to evaluate safety and efficacy of TT11 TT11 demonstrated compelling anti-tumor activity with complete disappearance of tumor observed in 8 of 14 patients Therapy well tolerated with no instances of…

